J&J extends tender offer for Omrix
This article was originally published in Scrip
Johnson & Johnson has extended its $438 million tender offer to buy Omrix Biopharmaceuticals, an Israeli developer of protein-based biosurgery and passive immunotherapies (Scrip Online, November 25th, 2008). The offer, originally due to expire at midnight (Eastern time) tomorrow will now end at midnight (Eastern time) on December 26th. J&J received clearance from the Israeli antitrust authorities earlier this month. The US company has tendered 23.4% of Omrix's common stock on a fully diluted basis to date.